Cencora, Inc. (NYSE:COR) Shares Sold by Versor Investments LP

Versor Investments LP decreased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 68.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,902 shares of the company's stock after selling 6,364 shares during the quarter. Versor Investments LP's holdings in Cencora were worth $652,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of COR. JFS Wealth Advisors LLC boosted its stake in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the period. Kentucky Trust Co purchased a new position in shares of Cencora during the 4th quarter worth about $33,000. Householder Group Estate & Retirement Specialist LLC grew its holdings in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the last quarter. WASHINGTON TRUST Co raised its position in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in Cencora in the third quarter worth about $41,000. Institutional investors own 97.52% of the company's stock.

Cencora Stock Down 0.3 %

Shares of COR traded down $0.84 during mid-day trading on Tuesday, hitting $254.54. The company's stock had a trading volume of 850,177 shares, compared to its average volume of 1,483,333. The firm has a market capitalization of $49.36 billion, a price-to-earnings ratio of 36.26, a PEG ratio of 1.31 and a beta of 0.49. The company's 50-day moving average is $242.26 and its 200-day moving average is $237.98. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research analyst reports. UBS Group raised their price target on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Barclays increased their target price on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Robert W. Baird boosted their target price on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Mizuho assumed coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target on the stock. Finally, Wells Fargo & Company lifted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Cencora currently has an average rating of "Moderate Buy" and a consensus price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.